On September 16, 2008, the U.S. Food and Drug Administration (
Site Search
Showing 71 - 80 of 137 results
News
|
Aug. 20, 2007
|
2 min read
News
|
Sept. 25, 2008
|
2 min read
News
|
July 16, 2008
|
1 min read
News
|
May 12, 2009
|
1 min read
News
|
Jan. 29, 2008
|
1 min read
Stem cells are a special type of
4 min read
The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.
News
|
Oct. 21, 2019
|
3 min read
The Cystic Fibrosis Foundation awarded up to $1.61 million to Eloxx Pharmaceuticals Inc. to conduct a U.S.-based Phase 2 clinical trial of an investigational drug that could potentially treat people with cystic fibrosis who have a nonsense mutation.
News
|
Sept. 23, 2019
|
2 min read